Navigation Links
MiMedx Announces Its Support Of New CMS Packaging Payment Policy For Skin Substitutes
Date:11/29/2013

ioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 200,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the clinical and cost effectiveness of EpiFix® and the resultant impact on the Company's market share, the effect of the new reimbursement system on putting the Company in a favorable position relative to its competitors and accelerating the growth in the Company's market share.  These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the potential that EpiFix® will not perform as expected or will not gain acceptance in the medical community, that the new reimbursement will not put the Co
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MiMedx To Present At Canaccord Genuity Medical Technology And Diagnostics Forum
2. MiMedx Announces Record Third Quarter Results
3. MiMedx Reports On Meeting With FDA
4. MiMedx Responds To Misleading And Inaccurate Media Reports
5. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
6. MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
7. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
8. MiMedx Announces Record Second Quarter Results
9. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
10. MiMedx To Exceed High End Of Second Quarter Guidance
11. MiMedx to Ring NASDAQ Stock Market Opening Bell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
... ... a standard tool in the chemical and pharmaceutical industries for providing information ... development and scale-up of chemical processes. METTLER TOLEDO is offering a ... Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today reported financial results ... a net loss for the third quarter of 2009 of $9.4 ... Company,s expectations. This compares to a net loss for the third ... Research and development expenses in the third quarter of 2009 were ...
... WILMINGTON, Del., Nov. 3 Fertili-Plus(TM) today introduced the ... 5-step, definitive, and easy-to-follow guide, when trying ... a free e-book publication, the Fertili-Plus Conception Framework equips ... their fertility and reproductive health, and increase their chances ...
Cached Biology Technology:Development of Batch and Continuous Chemical Processes Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Fertili-Plus Introduces 5-Step Conception Framework 2
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... issue of the journal Botany is set ... researchers are bringing to the study of pollination biology. ... researchers, examining topics that range from the effect of ... recent climate change on pollinator ranges. The issue also ...
... Ohio Loss of a particular microRNA in chronic lymphocytic ... mechanisms that enable cancer cells to produce the energy and ... tissue. , The findings come from a new study led ... Arthur G. James Cancer Hospital and Richard J. Solove ...
... the University of Colorado Boulder indicates air pollution in ... automobiles and agriculture is changing the alpine vegetation in ... nitrogen compounds to the atmosphere are being carried to ... CU-Boulder Professor William Bowman, who directs CU-Boulder,s Mountain Research ...
Cached Biology News:Special issue of Botany showcases CANPOLIN research 2miR loss may power maligant transformation in chronic leukemia 2Nitrogen pollution changing Rocky Mountain National Park vegetation, says CU-Boulder-led study 2Nitrogen pollution changing Rocky Mountain National Park vegetation, says CU-Boulder-led study 3
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Biology Products: